• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, May 13, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Utilization and cancer yield of BI-RADS 3 lesions detected on high risk screening breast MRI

Bioengineer by Bioengineer
May 7, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Results to be exhibited at 2019 ARRS Annual Meeting

Leesburg, VA, May 7, 2019–When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early stage breast cancer and avoid unnecessary biopsies, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI.

Utilization of MRI for breast cancer screening continues to increase, as it is the most sensitive modality to detect breast cancer. Yet, much more is known about short-term follow-up of probably benign findings (

Among the 6672 MRI screening exams performed in 3214 patients included in the study, 202 (3.0%) were assigned a BI-RADS 3. Among baseline exams, 8.3% (82/983) were assigned BI-RADS 3, compared to 2.1% (120/5689) of non-baseline exams (p

The results indicate BI-RADS 3 assessments are significantly more common in baseline versus non-baseline screening breast MRI exams, and BI-RADS 3 lesions on baseline exams have a lower cancer yield. Most cancers diagnosed on follow-up of BI-RADS 3 lesions are early stage and most are diagnosed at or before the 6-month follow-up. The results indicate that when employed sensibly, short-interval follow-up MRI is an appropriate technique to identify early stage breast cancer. “This study clarifies that probably benign assessments can be as useful for MRI as they are for mammography,” said co-author Leslie Lamb, MD, MSc, of Massachusetts General Hospital (MGH) and Harvard Medical School, both in Boston.

“Many patients and providers question the utility of BI-RADS 3 in MRI, particularly as some insurers do not cover the costs of the short interval follow-up MRIs. This study clarifies that short interval follow-up MRI is a valuable method of identifying early stage breast cancer while avoiding unnecessary biopsies.” noted co-author Christine Edmonds, MD, of the department of radiology at MGH.

###

With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2019 Annual Meeting, May 5-10, at the Hawaii Convention Center in Honolulu, Hawaii. For more information, visit: http://www.arrs.org/am19.

Media Contact
Alycia Tessean
[email protected]
https://arrs.org/ARRSLIVE/Pressroom/PressReleases/bi-rads-breast-mri-utilization-and-cancer-yield.aspx

Tags: Breast CancercancerDiagnosticsHealth Care Systems/ServicesHealth ProfessionalsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Breakthrough in CAR T Cell Therapy: Insights from Successfully Treated AML Patients

May 12, 2026

Comparing Immune-Related Adverse Events in Elderly Patients with Gastrointestinal and Lung Cancers

May 12, 2026

GDF15 Drives Chemotherapy Resistance in Colorectal Cancer

May 12, 2026

City of Hope Researchers to Present Groundbreaking Immunotherapy and Precision Medicine Advances Across Multiple Cancer Types at ASCO 2026

May 11, 2026
Please login to join discussion

POPULAR NEWS

  • Research Indicates Potential Connection Between Prenatal Medication Exposure and Elevated Autism Risk

    842 shares
    Share 337 Tweet 211
  • New Study Reveals Plants Can Detect the Sound of Rain

    728 shares
    Share 290 Tweet 182
  • Salmonella Haem Blocks Macrophages, Boosts Infection

    62 shares
    Share 25 Tweet 16
  • Breastmilk Balances E. coli and Beneficial Bacteria in Infant Gut Microbiomes

    57 shares
    Share 23 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Erin Roby Shares ECI Science Journey Insights

Immunogenetics Advances Personalised Psoriasis Diagnosis, Treatment

New Study Uncovers Rigorous Selection Patterns in Social Relationships

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.